Lexeo starts pivotal LX2006 trial, wins RMAT for LX2020

Lexeo Therapeutics reported second quarter 2026 results on August 12, 2026. In June 2026, Lexeo finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006 under the accelerated approval pathway, and the study was initiated in June with activation of the first trial site and enrollment of the first patient.¹ The company's CLARITY-FA natural history study continues enrolling across multiple US and global sites, and patients enrolled there are eligible to join SUNRISE-FA 2.¹

In June 2026, Lexeo announced publication of LX2006 data in JAMA Cardiology showing the therapy was generally well tolerated, with signs of efficacy in Phase I/II studies.¹ For LX2006, the company anticipates continued FDA engagement on confirmatory evidence strategy, a topline data readout in the second half of 2027, and a potential BLA submission under the accelerated approval pathway in the first half of 2028.¹

In August 2026, Lexeo received RMAT designation for LX2020 from the FDA based on recent interim data from its ongoing Phase I/II trial in PKP2 arrhythmogenic cardiomyopathy, a designation that provides opportunities for increased FDA interaction and may help expedite development.¹ LX2020 remains generally well tolerated across ten participants dosed, with no clinically significant complement activation to date.¹ The company expects a 12-month data update for all high dose participants in the fourth quarter of 2026 and regulatory engagement with the FDA later this year.¹

On the financial side, cash, cash equivalents and investments totaled $234.2 million as of June 30, 2026, which Lexeo believes will fund operations into 2028.¹ R&D expenses were $19.0 million in the quarter versus $14.7 million a year earlier, G&A expenses were $9.0 million versus $16.0 million, and net loss was $25.9 million, or $0.30 per share, compared with $26.1 million, or $0.60 per share, in the prior-year quarter.¹